<DOC>
	<DOC>NCT01884415</DOC>
	<brief_summary>The objective of this clinical trial is to compare the response rate obtained with two different vaccination schemes against HBV in cirrhotic patients. These patients must be candidates for liver transplantation, who have failed seroconversion (anti-HBs &lt; 10 IU/ml) after three intramuscular doses of 40 µg.</brief_summary>
	<brief_title>Phase III, Study to Evaluate the Efficacy of Two Different HBV Vaccination Schemes in Patients With Hepatic Cirrhosis</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Liver Cirrhosis</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>1. Cirrhotic patients, potential candidates for liver transplantation, with indication to HBV vaccination (HBsAg negative and antiHBs negative). 2. Patients under treatment with HBVAXPRO® who do not show a response after the first cycle of vaccination of three intramuscular doses of 40 µg at 0, 1 and 2 months. 3. Patients over 18 years old. 4. Negative pregnancy test. 5. Patients who have given their consent to participate in the study. 1. Absolute contraindication to HBV vaccine. 2. Medical history of allergy to any component of the vaccine. 3. Chronic renal failure on hemodialysis. 4. Presence of antibodies against Human Immunodeficiency Virus. 5. Patients with seroconversion (antiHBs &gt; 10 IU /ml) after the first three doses of vaccine. 6. Lack of consent to participate in the study.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>